Filter Results:
(258)
Show Results For
- All HBS Web
(120,194)
- Faculty Publications (258)
Show Results For
- All HBS Web
(120,194)
- Faculty Publications (258)
- January 2007 (Revised January 2007)
- Background Note
Note on the U.S. Food and Drug Administration
By: Robert F. Higgins, Richard G. Hamermesh and Virginia Fuller
Describes the U.S. FDA with particular emphasis on its role in the development of new drugs, biologic products, and medical devices today. Provides context for the drug approval process by describing the FDA's history and organizational structure. View Details
Keywords: Health; Governance Compliance; Policy; Product Development; Government and Politics; Pharmaceutical Industry; Medical Devices and Supplies Industry; Biotechnology Industry; Public Administration Industry; United States
Higgins, Robert F., Richard G. Hamermesh, and Virginia Fuller. "Note on the U.S. Food and Drug Administration." Harvard Business School Background Note 807-050, January 2007. (Revised January 2007.)
- January 2007
- Background Note
Note on Biotech Business Development
By: Richard G. Hamermesh and Robert F. Higgins
Describes the business development process in biotechnology companies. Topics covered include: participants in the licensing process and their interests, the major steps in the licensing process, the terms that are part of most agreements, and the most contentious... View Details
Keywords: Agreements and Arrangements; Entrepreneurship; Intellectual Property; Biotechnology Industry
Hamermesh, Richard G., and Robert F. Higgins. "Note on Biotech Business Development." Harvard Business School Background Note 807-032, January 2007.
- January 2007 (Revised June 2007)
- Background Note
Technology Transfer at U.S. Universities
By: Richard G. Hamermesh, Josh Lerner and David Kiron
Technology transfer from U.S. universities to industry has increased dramatically in the last 25 years. Reviews the history of technology transfer with particular emphasis on the Bayh-Dole Act of 1980. It then examines how universities responded to Bayh-Dole, the... View Details
Keywords: Higher Education; Information Technology; Laws and Statutes; Education Industry; Technology Industry; United States
Hamermesh, Richard G., Josh Lerner, and David Kiron. "Technology Transfer at U.S. Universities." Harvard Business School Background Note 807-124, January 2007. (Revised June 2007.)
- December 2006
- Supplement
Dental Corp--video
Hamermesh, Richard G. "Dental Corp--video." Harvard Business School Video Supplement 807-703, December 2006.
- November 2006 (Revised May 2007)
- Supplement
Corporate Venture Capital at Eli Lilly
Hamermesh, Richard G. "Corporate Venture Capital at Eli Lilly." Harvard Business School Video Supplement 807-705, November 2006. (Revised May 2007.)
- October 2006 (Revised August 2007)
- Case
Calloway Laboratory: Pee for Profit
By: Richard G. Hamermesh and David Kiron
Describes the formation and rapid growth of a drug-testing company. The company needs to decide whether to enter the painkiller testing market, in addition to growing its drug treatment center business. View Details
Keywords: For-Profit Firms; Health Care and Treatment; Health Testing and Trials; Growth and Development Strategy; Market Entry and Exit; Health Industry
Hamermesh, Richard G., and David Kiron. "Calloway Laboratory: Pee for Profit." Harvard Business School Case 807-040, October 2006. (Revised August 2007.)
- September 2006
- Teaching Note
Corporate Venture Capital at Eli Lilly (TN)
By: Richard G. Hamermesh and Erin Seefeld
- September 2006
- Supplement
Wu Xi Pharmatech
Keywords: Pharmaceutical Industry
Hamermesh, Richard G. "Wu Xi Pharmatech." Harvard Business School Video Supplement 807-701, September 2006.
- June 2006
- Supplement
Cutlass Capital, L.P.: Discussion with David Hetz and Jon Osgood
Hamermesh, Richard G. "Cutlass Capital, L.P.: Discussion with David Hetz and Jon Osgood." Harvard Business School Video Supplement 806-719, June 2006.
- 2006
- Book
New Business Ventures and the Entrepreneur
By: Michael J. Roberts, Howard H. Stevenson, William A. Sahlman, Paul Marshall and Richard G. Hamermesh
Keywords: Entrepreneurship
Roberts, Michael J., Howard H. Stevenson, William A. Sahlman, Paul Marshall and Richard G. Hamermesh, eds. New Business Ventures and the Entrepreneur. 6th ed. New York: McGraw-Hill/Irwin, 2006.
- May 2006
- Teaching Note
WuXi PharmaTech (TN)
By: Richard G. Hamermesh and Erin Seefeld
Keywords: Pharmaceutical Industry
- March 2006
- Teaching Note
Cutlass Capital, L.P. (TN)
By: Richard G. Hamermesh and Erin Seefeld
Teaching Note to 805075. View Details
Keywords: Financial Services Industry
- March 2006
- Teaching Note
Conor Medsystems (TN)
By: Robert F. Higgins, Richard G. Hamermesh and Erin Seefeld
Teaching Note to (804-180). View Details
Keywords: Health Industry
- March 2006
- Teaching Note
Stan Lapidus: Profile of a Medical Entrepreneur (TN)
By: Robert F. Higgins, Richard G. Hamermesh and Erin Seefeld
Teaching Note to (805-087). View Details
- March 2006
- Teaching Note
Fred Khosravi and AccessClosure (TN)
By: Richard G. Hamermesh and Erin Seefeld
Teaching Note to (806-044). View Details
- March 2006 (Revised February 2009)
- Teaching Note
Molecular Insight Pharmaceuticals, Inc. (TN)
By: Richard G. Hamermesh and Erin Seefeld
Teaching Note to (805-067). View Details
Keywords: Pharmaceutical Industry
- February 2006 (Revised July 2007)
- Case
Corporate Venture Capital at Eli Lilly
By: Richard G. Hamermesh, Ron Laufer and David Lane
Reviews the role of corporate venture capital and its history at Eli Lilly. Also presents a challenging venture investment opportunity. View Details
Hamermesh, Richard G., Ron Laufer, and David Lane. "Corporate Venture Capital at Eli Lilly." Harvard Business School Case 806-092, February 2006. (Revised July 2007.)
- February 2006
- Teaching Note
John Moran and the Orthopedics Industry (TN)
Teaching Note to 805026. View Details
Keywords: Health Industry
- January 2006 (Revised May 2007)
- Case
Endo Pharmaceuticals (A): From LBO to...?
By: Richard G. Hamermesh and Brian DeLacey
Endo Pharmaceuticals was formed in 1997 as a leveraged buyout spin-off from DuPont Merck. In 1999, it must decide whether to do an IPO or merge with a smaller company. View Details
Keywords: Private Equity; Initial Public Offering; Leveraged Buyouts; Mergers and Acquisitions; Health Care and Treatment; Pharmaceutical Industry; United States
Hamermesh, Richard G., and Brian DeLacey. "Endo Pharmaceuticals (A): From LBO to...?" Harvard Business School Case 806-064, January 2006. (Revised May 2007.)
- January 2006 (Revised May 2007)
- Supplement
Endo Pharmaceuticals (B): Merger Decision
By: Richard G. Hamermesh and Brian DeLacey
Hamermesh, Richard G., and Brian DeLacey. "Endo Pharmaceuticals (B): Merger Decision." Harvard Business School Supplement 806-065, January 2006. (Revised May 2007.)